Read by QxMD icon Read

Testosterone replacement therapy

Mario Maggi, Frederick C W Wu, Thomas H Jones, Graham Jackson, Hermann M Behre, Geoffrey Hackett, Antonio Martin-Morales, Giancarlo Balercia, Adrian S Dobs, Stefan T E Arver, Marcello Maggio, Glenn R Cunningham, Andrea M Isidori, Richard Quinton, Olivia A Wheaton, Flora S Siami, Raymond C Rosen
AIMS: The aim of this study was to assess cardiovascular (CV) safety of testosterone replacement therapy (TRT) in a large, diverse cohort of European men with hypogonadism (HG). METHODS: The Registry of Hypogonadism in Men (RHYME) was designed as a multi-national, longitudinal disease registry of men diagnosed with hypogonadism (HG) at 25 clinical sites in six European countries. Data collection included a complete medical history, physical examination, blood sampling and patient questionnaires at multiple study visits over 2-3 years...
October 2016: International Journal of Clinical Practice
Yu Seob Shin, Jae Hyung You, Jai Seong Cha, Jong Kwan Park
OBJECTIVE: To investigate the relationship between serum total testosterone (TT) and free testosterone (FT) levels in men with anemia. METHODS: We reviewed the records of 1221 subjects between March 2009 and December 2014. All the subjects' blood samples were drawn for TT and FT assays. Their serum hemoglobin (Hb) and serum hematocrit (Hct) levels were measured. The primary objective of our study was to investigate the association between TT and FT levels with Hb and Hct levels...
October 18, 2016: Aging Male: the Official Journal of the International Society for the Study of the Aging Male
Adam C Millar, Dean S Elterman, Larry Goldenberg, Brandon Van Asseldonk, Ashley Curtis, Keith Jarvi
INTRODUCTION: Attitudes regarding the safety of testosterone replacement therapy (TRT) in hypogonadal men with prostate cancer (PCa) have changed over the past few years with the emergence of case studies suggesting a low risk of cancer progression and a better understanding of the interaction of different levels of androgen with prostate cellular metabolism. This new view has the potential to change clinical practice. METHODS: Active members of the Canadian Urological Association were surveyed about their opinions on the safety of TRT in men with low-risk PCa, as well as their current prescribing habits...
May 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
Y-X Kang, Y-J Wang, Q Zhang, X-H Pang, W Gu
Kearns-Sayre syndrome (KSS) is a disorder caused by mutations in mitochondrial DNA. Here, we report an unusual case of Kearns-Sayre syndrome accompanied by hypopituitarism (deficiencies in reproductive and growth hormones). A 20-year-old male presented with growth retardation for the last 8 years, as well as the following findings: short stature, delayed puberty, myasthenia, an extraocular movement deficit, drooping eyelids, pectus carinatum and scoliosis. Cerebral enhanced magnetic resonance imaging revealed dysplasias of the pituitary, white matter and cerebellum...
October 6, 2016: Andrologia
Heather L Gelhorn, Ebony Dashiell-Aje, Michael G Miller, Leonard R DeRogatis, Adrian Dobs, Allen D Seftel, Stanley E Althof, Meryl Brod, Dennis A Revicki
INTRODUCTION: The Hypogonadism Impact of Symptoms Questionnaire (HIS-Q) is a patient-reported outcome measurement designed to comprehensively evaluate the symptoms of hypogonadism and to detect changes in these symptoms in response to treatment. AIM: To conduct item analysis and reduction, evaluate the psychometric properties of the HIS-Q, and provide guidance on interpreting the instrument score. METHODS: A 12-week observational, longitudinal study of hypogonadal men was conducted...
September 27, 2016: Journal of Sexual Medicine
A Tölli, J Borg, B-M Bellander, F Johansson, C Höybye
PURPOSE: Reports on long-term variations in pituitary function after traumatic brain injury (TBI) and subarachnoid haemorrhage (SAH) diverge. The aim of the current study was to evaluate the prevalence and changes in pituitary function during the first year after moderate and severe TBI and SAH and to explore the relation between pituitary function and injury variables. METHODS: Adults with moderate and severe TBI or SAH were evaluated at 10 days, 3, 6 and 12 months post-injury/illness...
September 26, 2016: Journal of Endocrinological Investigation
Oluwadamilola Onasanya, Geetha Iyer, Eleanor Lucas, Dora Lin, Sonal Singh, G Caleb Alexander
Given the conflicting evidence regarding the association between exogenous testosterone and cardiovascular events, we systematically assessed published systematic reviews for evidence of the association between exogenous testosterone and cardiovascular events. We searched PubMed, MEDLINE, Embase, Cochrane Collaboration Clinical Trials,, and the US Food and Drug Administration website for systematic reviews of randomised controlled trials published up to July 19, 2016. Two independent reviewers screened 954 full texts from 29 335 abstracts to identify systematic reviews of randomised controlled trials in which the cardiovascular effects of exogenous testosterone on men aged 18 years or older were examined...
September 23, 2016: Lancet Diabetes & Endocrinology
Takeshi Hashimoto, Krishnan Rahul, Toshikazu Takeda, Nicole Benfante, John P Mulhall, Hedvig Hricak, James A Eastham, Hebert Alberto Vargas
OBJECTIVE: To investigate the multiparametric prostate magnetic resonance imaging (mpMRI) findings in patients treated with testosterone replacement therapy (TRT) while on active surveillance for low-risk prostate cancer. METHODS: We retrospectively reviewed 12 patients who underwent mpMRI before and after TRT while on active surveillance. Changes in serum testosterone level, prostate-specific antigen (PSA), prostate biopsy findings, prostate volume, and Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) score before and after TRT were summarized...
September 21, 2016: Urologic Oncology
Timothy K O'Rourke, Matthew S Wosnitzer
Opioid-induced androgen deficiency (OPIAD) was initially recognized as a possible consequence of opioid use roughly four decades ago. Long-acting opioid use carries risks of addiction, tolerance, and systemic side effects including hypogonadotropic hypogonadism with consequent testosterone depletion leading to multiple central and peripheral effects. Hypogonadism is induced through direct inhibitory action of opioids on receptors within the hypothalamic-pituitary-gonadal (HPG) and hypothalamic-pituitary-adrenal (HPA) axes as well as testosterone production within the testes...
October 2016: Current Urology Reports
Zhi-Yuan Zhang, Xiao-Yu Xing, Guan-Qun Ju, Liang Zhong, Jie Sun
Androgen deficiency is a physical disorder that not only affects adults but can also jeopardize children's health. Because there are many disadvantages to using traditional androgen replacement therapy, we have herein attempted to explore the use of human umbilical cord mesenchymal stem cells for the treatment of androgen deficiency. We transplanted CM-Dil-labeled human umbilical cord mesenchymal stem cells into the testes of an ethane dimethanesulfonate (EDS)-induced male rat hypogonadism model. Twenty-one days after transplantation, we found that blood testosterone levels in the therapy group were higher than that of the control group (P = 0...
August 30, 2016: Asian Journal of Andrology
Charles J Glueck, Vybhav Jetty, Naila Goldenberg, Parth Shah, Ping Wang
We compared thrombophilia and hypofibrinolysis in 6 men with Klinefelter syndrome (KS), without previously known familial thrombophilia, who had sustained deep venous thrombosis (DVT)-pulmonary emboli (PE) or mesenteric artery thrombosis on testosterone replacement therapy (TRT). After the diagnosis of KS, TRT had been started in the 6 men at ages 11, 12, 13, 13, 19, and 48 years. After starting TRT, DVT-PE or mesenteric artery thrombosis was developed in 6 months, 1, 11, 11, 12, and 49 years. Of the 6 men, 4 had high (>150%) factor VIII (177%, 192%, 263%, and 293%), 3 had high (>150%) factor XI (165%, 181%, and 193%), 1 was heterozygous for the factor V Leiden mutation, and 1 was heterozygous for the G20210A prothrombin gene mutation...
August 31, 2016: Clinical and Applied Thrombosis/hemostasis
Bu B Yeap, Mathis Grossmann, Robert I McLachlan, David J Handelsman, Gary A Wittert, Ann J Conway, Bronwyn Ga Stuckey, Douglas W Lording, Carolyn A Allan, Jeffrey D Zajac, Henry G Burger
INTRODUCTION: Part 1 of this position statement dealt with the assessment of male hypogonadism, including the indications for testosterone therapy. This article, Part 2, focuses on treatment and therapeutic considerations for male hypogonadism and identifies key questions for future research. MAIN RECOMMENDATIONS: Key points and recommendations are:Excess cardiovascular events have been reported in some but not all studies of older men without pathological hypogonadism who were given testosterone treatment...
September 5, 2016: Medical Journal of Australia
Michaël R Laurent, Christine Helsen, Leen Antonio, Dieter Schollaert, Steven Joniau, Michel J Vos, Brigitte Decallonne, Geoffrey L Hammond, Dirk Vanderschueren, Frank Claessens
Biochemical assessments of androgen status (hyper- or hypoandrogenism) are usually based on serum testosterone concentrations. According to the free hormone hypothesis, sex hormone-binding globulin (SHBG) determines free and bioavailable testosterone concentrations. Previous studies have suggested that in vitro androgen bioassay results may also be influenced by SHBG and correlate with free or bioavailable testosterone concentrations. To test this hypothesis, we established a stable HEK293 cell line with high expression of the human androgen receptor (AR) and a luciferase reporter downstream of a classical androgen response element...
December 5, 2016: Molecular and Cellular Endocrinology
Giovanni Corona, Giulia Rastrelli, Elisa Maseroli, Alessandra Sforza, Mario Maggi
[This corrects the article on p. 130 in vol. 33, PMID: 26770933.].
August 2016: World Journal of Men's Health
Gabriela Cobo, Paloma Gallar, Cristina Di Gioia, Concepción García Lacalle, Rosa Camacho, Isabel Rodriguez, Olimpia Ortega, Carmen Mon, Ana Vigil, Bengt Lindholm, Juan Jesús Carrero
BACKGROUND: Testosterone deficiency (hypogonadism) is common among men undergoing haemodialysis, but its clinical implications are not well characterized. Testosterone is an anabolic hormone that induces erythrocytosis and muscle synthesis. We hypothesized that testosterone deficiency would be associated with low muscle mass, physical inactivity and higher dosages of erythropoietin-stimulating agents (ESA). METHODS: Single-center cross-sectional study of 57 male haemodialysis patients...
August 20, 2016: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
Aydogan Aydogdu, Ronald S Swerdloff
INTRODUCTION: Male hypogonadism is characterized by inadequate production of Testosterone (T) (hypoandrogenism) and deficiencies in spermatogenesis. The main treatment of male hypogonadism is T replacement therapy (TRT), but for some of the patients, alternative drugs may be more suitable. AREAS COVERED: The available literature of T and alternative treatments for male hypogonadism are discussed. EXPERT OPINION: Transdermal application of T gels are the most commonly used route of T administration...
September 2016: Expert Opinion on Emerging Drugs
L Lašaitė, J Čeponis, R T Preikša, B Žilaitienė
The aim of the study was to examine the effects of two-year testosterone replacement therapy on cognitive functioning, emotional state and quality of life in young and middle-aged men with hypogonadotropic hypogonadism. Nineteen males diagnosed with hypogonadotropic hypogonadism participated in the study. Cognitive functions were assessed by Trail Making Test and Digit Span Test of Wechsler Adult Intelligence Scale. Emotional state was evaluated by Profile of Mood States. Quality of life was evaluated by WHO Brief Quality of Life Questionnaire...
August 22, 2016: Andrologia
Kevin R Loughlin, Julia Klap
No abstract text is available yet for this article.
November 2016: Journal of Urology
Fuat Kizilay, Helena Elizabeth Gali, Ege Can Serefoglu
INTRODUCTION: Deterioration in sexual functioning is one of the major and serious complications of diabetes. This common metabolic disorder not only affects sexuality through microvascular and nerve damage but also has psychological aspects. In men, the primary complications are erectile dysfunction, ejaculatory dysfunction, and loss of libido. Women similarly experience sexual problems, including decreased libido and painful intercourse. AIM: To summarize the effects of diabetes on sexuality, evaluate the impact of diabetes on sexual function, and assess the conventional and novel treatment approaches based on recent studies...
August 17, 2016: Sexual Medicine Reviews
Diana Martins, Zhan Yao, Mina Tadrous, Baiju R Shah, David N Juurlink, Muhammad M Mamdani, Tara Gomes
PURPOSE: To examine the concordance between testosterone replacement therapy (TRT) use and established reimbursement criteria, as well as compare the persistence of use among available formulations (injectable, oral, topical gel, transdermal patch) among elderly men in Ontario, Canada. METHODS: We conducted a retrospective cohort study of men aged 66 years or older in Ontario newly treated with testosterone between 1 January 2009 and 31 December 2012 using linked health administrative data...
August 16, 2016: Pharmacoepidemiology and Drug Safety
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"